A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

Phase 3RecruitingNCT06441630

Addpharma Inc.251 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Essential Hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

251

Conditions

Essential Hypertension

Interventions

AD-227ADRUG

Per Oral, 1 Tablet, Once a day for 8 weeks

AD-227BDRUG

Per Oral, 1 Tablet, Once a day for 8 weeks

AD-227CDRUG

Per Oral, 1 Tablet, Once a day for 8 weeks

Placebo of AD-227B

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Patients with Essential Hypertension * Other inclusions applied Exclusion Criteria: * Patient with Secondary Hypertension * Other exclusions applied

Locations (1)

Gangnam CHA Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Change in MSSBP

Change from Baseline in Mean Sitting Systolic Blood Pressure

Time frame: Baseline to Week8

Central Contacts

JeongEun Park

CONTACT

+82-31-891-6989 parkje@addpharma.co.kr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.